Clinical Trial Update: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports safety, immunogenicity, and LDL-C lowering activity of two AFFITOPE vaccines targeting PCSK9 in healthy subjects; the study ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• AFFITOPE PCSK9 vaccine - Variant A
• AFFITOPE PCSK9 vaccine - Variant B

Snippet

Sponsor: Affiris AG | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED